GENITOURINARY CANCERS

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses results from a trial that evaluated tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) when using the Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.

A meta-analysis presented during the 10th Annual Genitourinary Cancers Symposium found that when used with other therapies for the treatment of mCRPC, prednisone does not raise the risk for severe toxicities, nor does it affect overall survival (OS).

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.

Patients with bone metastatic castration-resistant prostate cancer (CRPC) who received radium-223 dichloride (Xofigo) continued to have a low incidence of myelosuppression and no associated secondary malignancies at a 1.5-year follow-up of the pivotal phase III ALSYMPCA study that was presented at the 2014 Genitourinary Cancers Symposium.

Matthew D. Galsky, MD, from The Mount Sinai Hospital, discusses an analysis of the distribution and geographic accessibility of prostate cancer clinical trials in the U.S.

Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.

Improved outcomes continued to be demonstrated with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer, according to an updated analysis, conducted after 11 years of observation.

Enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%.

The premature termination of clinical trials in the oncology setting is a problem that continues to vex researchers, and results of a new study that involved more than 7500 adult cancer clinical trials suggest that the concern is justified.

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, discusses the utility of PET imaging for the treatment of patients with prostate cancer.

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

Targeted Oncology interviewed Cy Stein, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology and deputy director of Clinical Research at City of Hope National Medical Center.

A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with mCRPC, a recent analysis of the phase III COU-AA-30 pivotal trial demonstrated.

Evan Y. Yu, MD, discusses the role of PET imaging in prostate cancer.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.

William Kevin Kelly, DO, discusses the role of chemotherapy in castration-resistant prostate cancer.

An interview with James Mohler, MD, associate director and senior vice president for Translational Research at Roswell Park Cancer Institute, Buffalo, NY, and chair of the NCCN Guidelines Panel for Prostate Cancer.

Over the past three years, diverse new therapies have been approved to treat advanced prostate cancer, including agents that have shown some promise in delaying its progression to the bone.

Targeted Oncology spoke with Padmanee Sharma, MD, PhD, about advances in immunotherapy for castration-resistant prostate cancer (CRPC).

Leonard G. Gomella, MD, FACS, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer.

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.

A phase III trial examining the anti-CTLA-4 immune checkpoint inhibitor ipilimumab (Yervoy) in men with metastatic castration-resistant prostate cancer (mCRPC) failed to meet its primary endpoint of prolongation in overall survival (OS).

Amid a flurry of new drug approvals in recent years, the American Urological Association (AUA) has issued its first set of guidelines for the management of patients with metastatic castration-resistant prostate cancer (mCRPC).

Over the past two decades, there has been a shift away from indiscriminate cell-killing by anticancer agents toward the development of more specific drugs that target key aspects of cancer cell biology.

Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.

James L. Gulley, MD, PhD, discusses how PROSTVAC works in patients with castration-resistant prostate cancer.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Long-term safety and efficacy results from COU-AA-302 in mCRPC, and efficacy and safety data for enzalutamide monotherapy were among the ASCO 2013 Annual Meeting presentations that extended clinically useful information for the care of patients with prostate cancer.